Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kathleen B. Orrico"'
Autor:
Kathleen B Orrico
Publikováno v:
Drug Target Insights, Vol 13, Iss 1 (2019)
Abstract non disponibile
Externí odkaz:
https://doaj.org/article/dae9eeea96c5409596b3e08cf895982d
Autor:
Kathleen B. Orrico
Publikováno v:
Drug Target Insights
This basic review of genetic principles will aid pharmacists in preparing for their eventual role of translating gene-drug associations into clinical practice. Genes, which are stretches of deoxyribonucleic acid (DNA) contained on the 23 pairs of hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a71f6a29537a35506e4299167f4e714
https://pubmed.ncbi.nlm.nih.gov/31832012
https://pubmed.ncbi.nlm.nih.gov/31832012
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 9:126-134
Background— Trial data for the benefits and risks of dabigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world observational evidence for the comparative effectiveness and safety of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f66b40849410d34d706fe87341f037d3
https://doi.org/10.1161/circoutcomes.115.002369
https://doi.org/10.1161/circoutcomes.115.002369
Autor:
Kathleen B. Orrico
Publikováno v:
Journal of the American Pharmacists Association. 53:e142-e150
Objective To raise pharmacist awareness about the needs and concerns of our patients with visual impairment and to review useful strategies to foster medication adherence. Summary As patient-centered pharmacists, we need to understand the challenges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8301cee07eb7539609ae38ff7aaa29d5
https://doi.org/10.1331/japha.2013.13514
https://doi.org/10.1331/japha.2013.13514
Autor:
Kathleen B. Orrico
Publikováno v:
Journal of Managed Care Pharmacy. 14:626-631
BACKGROUND: Accuracy and transportability of the recorded outpatient medication list are important in the continuum of patient care. Classifying discrepancies between the electronic medical record (EMR) and actual drug use by the root cause of discre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8171fda2a1098b012797d7ee558c9f71
https://doi.org/10.18553/jmcp.2008.14.7.626
https://doi.org/10.18553/jmcp.2008.14.7.626
Publikováno v:
The Annals of pharmacotherapy. 48(9)
Background: An analysis of the US Food and Drug Administration’s Adverse Event Reporting System database found evidence suggesting that the combination of the cholesterol-lowering drug pravastatin and the antidepressant paroxetine, produced a signi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13272b27b3c3156d566ff649aeab20aa
https://pubmed.ncbi.nlm.nih.gov/24928102
https://pubmed.ncbi.nlm.nih.gov/24928102
Publikováno v:
Journal of managed care pharmacy : JMCP. 17(9)
BACKGROUND: Recent quality initiatives require that the routine annual therapeutic drug-monitoring (TDM) parameters for the high-risk medication digoxin include a measure of renal function and a serum potassium level but not a serum digoxin concentra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0345347b4442d6abe8fd867753c4712
https://pubmed.ncbi.nlm.nih.gov/22050394
https://pubmed.ncbi.nlm.nih.gov/22050394
Publikováno v:
The American journal of managed care. 16(5)
On May 21, 2007, a safety alert was widely disseminated through the media and US Food and Drug Administration (FDA) MedWatch concerning a possible increased risk of ischemic myocardial infarction and cardiovascular death in people receiving the antid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1180bfa4d2028afff45aecd1b6c0fb64
https://pubmed.ncbi.nlm.nih.gov/20455636
https://pubmed.ncbi.nlm.nih.gov/20455636
Autor:
Gayle A. Brazeau, Kathleen B. Orrico, Nancy DeGuire, William G. Lang, Heidi C. Marchand, Anna Legreid Dopp, James P. Kehrer
Publikováno v:
American journal of pharmaceutical education.
According to the Bylaws of the AACP, the Advocacy Committee: “will advise the Board of Directors on the formation of positions on matters of public policy and on strategies to advance those positions to the public and private sectors on behalf of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04ddc20f55e98f109c964486a374f5f
https://pubmed.ncbi.nlm.nih.gov/20221390
https://pubmed.ncbi.nlm.nih.gov/20221390